We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Women in England are being encouraged to help shape reproductive health policy by sharing their experiences, as the government launches a landmark survey.
Update of sexual and reproductive health profile indicators for reproductive health including abortions, birth outcomes and contraceptive use.
Urgent action continues to be taken to ensure women across the UK will be able to more reliably access HRT products.
Women who are current or past users of hormone replacement therapy (HRT) to treat symptoms of the menopause are reminded to be vigilant for signs of breast cancer, even after stopping HRT.
Risk of meningioma with cyproterone acetate increases with increasing cumulative dose. Use of cyproterone is contraindicated in patients with previous or current meningioma (for all indications) and should only be considered for control of libido in severe hypersexuality or paraphilias...
There will be new restrictions on exporting hormone replacement therapy (HRT) products, which currently face supply shortages due to manufacturing issues.
A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.
Premature puberty and genital enlargement have been reported in children who were in close physical contact with an adult using topical testosterone and who were repeatedly accidentally exposed to this medicine. To reduce these risks, advise patients to wash their...
Employers are being encouraged to better support women experiencing the menopause as the Government today appointed England’s first ever Menopause Employment Champion.
Ministers and senior clinicians from across all 4 nations will come together today for the inaugural meeting of the UK Menopause Taskforce.
Women across the country to benefit from better access to care for essential services for menstrual problems, contraception, pelvic pain and menopause care.
The government has published the first ever Women's Health Strategy for England to tackle the gender health gap.
If a patient reports persistent symptoms when switching between different levothyroxine tablet formulations, consider consistently prescribing a specific product known to be well tolerated by the patient. If symptoms or poor control of thyroid function persist (despite adhering to a...
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Increased risk of stroke in older women should be taken into account in prescribing decisions.
Public call for evidence launched relating to the use of hormonal pregnancy tests.
Levonorgestrel-releasing intrauterine systems should always be prescribed by brand name because products have different indications, durations of use, and introducers.
Following extensive changes to the formulation and manufacture of levothyroxine tablets by Teva, the Commission on Human Medicines (CHM) is now reassured that Teva has demonstrated an acceptable level of efficacy and safety to allow their levothyroxine tablets to re-enter...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.